Evaluation of Varenicline Safety, Tolerability, Pharmacokinetics and Pro-Cognitive Effects in Healthy Elderly Non-Smoking Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
HealthyNon-Smoking
Interventions
DRUG

varenicline

0.5 mg once daily for 7days followed by 0.5 mg twice daily for 7days followed by 1mg twice daily for 7 days

DRUG

varenicline

0.5 mg once daily for 14 days followed by 1 mg once daily for 7 days

DRUG

varenicline

0.5 mg once daily for 14 days followed by 0.5 mg twice daily for 7 days

DRUG

Placebo

Placebo for 21 days

Trial Locations (2)

32809

Pfizer Investigational Site, Orlando

33169

Pfizer Investigational Site, Miami

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY